Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , reported its financial results for the first quarter ended March 31, 2014. Targacept , Inc. (NASDAQ:TRGT), shares after opening at $4.00 moved to $4.24 on last trade day and at the end of the day closed at $4.11. Company price to sales ratio in past twelve months was calculated as 38.57 and price to cash ratio as 1.50. Targacept , Inc. (NASDAQ:TRGT), showed a negative weekly performance of 7.43%.
Northwest Biotherapeutics, Inc (NASDAQ:NWBO)’s shares dropped 5.44% to $6.78. The company on Apr. 7 again set the record straight: Adam Feuerstein’s latest, sensationalized headline claims about the Company’s annual report and Phase III trial are once again factually wrong and materially misleading. Northwest Biotherapeutics, Inc (NASDAQ:NWBO), shares fell 5.43% in last trading session and ended the day on $5.22. Northwest Biotherapeutics, Inc (NASDAQ:NWBO), return on equity ratio is recorded as 543.80% and its return on assets is -898.30%. Northwest Biotherapeutics, Inc (NASDAQ:NWBO), yearly performance is 47.46%.
Neuralstem, Inc. (NYSEMKT:CUR), announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. Neuralstem, Inc. (NYSEMKT:CUR), shares moved down 7.08% in last trading session and was closed at $3.15, while trading in range of $ 3.05 -3.45. Neuralstem, Inc. (NYSEMKT:CUR), year to date (YTD) performance is 8.25%.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), announced its earnings results on Tuesday. The company reported ($0.12) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.01,Analyst Ratings News reports. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $6.59 million. Sangamo Biosciences, Inc. (NASDAQ:SGMO), weekly performance is -15.03%. On last trading day company shares ended up $11.76. Sangamo Biosciences, Inc. (NASDAQ:SGMO), distance from 50-day simple moving average (SMA50) is -33.58%. Analysts mean target Price for the company is $27.33.
Leave a Reply